Citadel Advisors
ASMB icon

Citadel Advisors’s Assembly Biosciences ASMB Stock Holding History

Citadel Advisors’s Portfolio ASMB Stock Details ASMB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-48
Closed -$659 – 14206
2024
Q2 		$659 Buy
+48
New +$685 ﹤0.01% 13939
2024
Q1 		– Sell
-250
Closed -$2.46K – 14512
2023
Q4 		$2.46K Sell
250
-633
-72% -$6.02K ﹤0.01% 13695
2023
Q3 		$9.38K Sell
883
-384
-30% -$4.63K ﹤0.01% 13130
2023
Q2 		$17.5K Sell
1,267
-991
-44% -$12.2K ﹤0.01% 12846
2023
Q1 		$22.8K Buy
2,258
+766
+51% +$12.9K ﹤0.01% 12968
2022
Q4 		$23.3K Buy
+1,492
New +$25.5K ﹤0.01% 13023
2022
Q3 		– Sell
-3,175
Closed -$80K – 12567
2022
Q2 		$80K Buy
3,175
+350
+12% +$8.05K ﹤0.01% 11591
2022
Q1 		$70K Buy
2,825
+1,492
+112% +$32K ﹤0.01% 12576
2021
Q4 		$37K Buy
+1,333
New +$43.7K ﹤0.01% 13397
2021
Q3 		– Sell
-1,717
Closed -$80K – 13766
2021
Q2 		$80K Buy
1,717
+25
+1% +$1.24K ﹤0.01% 13077
2021
Q1 		$93K Sell
1,692
-175
-9% -$11.6K ﹤0.01% 12527
2020
Q4 		$136K Sell
1,867
-450
-19% -$52.8K ﹤0.01% 10005
2020
Q3 		$457K Buy
2,317
+1,459
+170% +$367K ﹤0.01% 7457
2020
Q2 		$240K Sell
858
-384
-31% -$89.6K ﹤0.01% 8264
2020
Q1 		$221K Sell
1,242
-483
-28% -$104K ﹤0.01% 7842
2019
Q4 		$424K Buy
+1,725
New +$318K ﹤0.01% 7066
2019
Q2 		– Sell
-1,300
Closed -$307K – 9136
2019
Q1 		$307K Buy
1,300
+425
+49% +$108K ﹤0.01% 7585
2018
Q4 		$238K Buy
875
+108
+14% +$31.2K ﹤0.01% 7618
2018
Q3 		$342K Buy
+767
New +$359K ﹤0.01% 7359
2018
Q2 		– Sell
-2,608
Closed -$1.54M – 8791
2018
Q1 		$1.54M Buy
2,608
+2,033
+354% +$1.26M ﹤0.01% 4132
2017
Q4 		$312K Buy
+575
New +$260K ﹤0.01% 6395
2014
Q3 		– Sell
-73
Closed -$6K – 8090
2014
Q2 		$6K Buy
73
+46
+170% +$3.26K ﹤0.01% 7692
2014
Q1 		$2K Buy
+27
New +$4.21K ﹤0.01% 7720

Other funds holding ASMB

GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PHP
Parkman Healthcare Partners Stamford, Connecticut $970M AUM 79.46% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return

Citadel Advisors's ASMB Position: Q1 2026 in Review

Citadel Advisors reduced its Assembly Biosciences (ASMB) stake by 23% in Q1 2026, selling an estimated $212K and leaving 25,437 shares worth $706K. The position accounts for ﹤0.01% of the portfolio, ranked #8475.

Citadel Advisors first reported a position in ASMB in Q1 2014 and has held it in 32 quarters since. The position peaked at $27.1M in Q2 2020. 75 funds tracked by Wall St. Rank hold ASMB as of Q1 2026.

  • Citadel Advisors held 25,437 shares of Assembly Biosciences worth $706K as of Q1 2026.
  • Citadel Advisors sold 7,429 Assembly Biosciences shares in Q1 2026, an estimated $212K.
  • Assembly Biosciences made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #8475 holding.
  • Citadel Advisors first reported a position in Assembly Biosciences in Q1 2014 and has held it in 32 quarters since.
  • Citadel Advisors's Assembly Biosciences position peaked at $27.1M in Q2 2020.
  • 75 funds tracked by Wall St. Rank held Assembly Biosciences as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.